PDF(Pubmed)
Abstract：
UNASSIGNED: Tranexamic acid (TXA) has been used to improve bleeding outcomes in many surgical procedures. However, its blood-sparing effect in liposuction is not well established.
UNASSIGNED: A systematic literature search was performed using PubMed, Embase, Cumulated Index to Nursing and Allied Health Literature (CINAHL), Cochrane Central, ClinicalTrials.gov, and WorldWideScience.org databases from their inception to October 8, 2021, according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The authors focused on 3 main topics: 1) TXA, 2) liposuction, and 3) complications. We included articles evaluating the potential blood-sparing effects of TXA in liposuction. Studies were excluded if they were systematic review articles or protocol papers, animal studies, conference abstracts, survey studies, or non-English publications.
UNASSIGNED: A total of 711 articles were identified, with 1 retrospective and 4 prospective (3 randomized) studies meeting our inclusion criteria. TXA was used in various forms: administered intravenously either on induction or after the procedure, mixed into the tumescent solution, or infiltrated into the liposuction sites after lipoaspiration. A significantly smaller reduction in hematocrit was noted in the TXA group compared with that in the non-TXA group (p<0.001) despite a significantly greater amount of lipoaspirate removed in the TXA group (p<0.001). Patients in non-TXA cohorts experienced adverse effects (such as seroma and need for transfusion) that were not seen in TXA cohorts.
UNASSIGNED: TXA use in patients undergoing liposuction seems to be associated with a beneficial blood-sparing effect, which may enhance safety in this population. Future studies should aim to determine the optimal route and dosing for TXA in liposuction.
UNASSIGNED: Level IV.
UNASSIGNED: A systematic literature search was performed using PubMed, Embase, Cumulated Index to Nursing and Allied Health Literature (CINAHL), Cochrane Central, ClinicalTrials.gov, and WorldWideScience.org databases from their inception to October 8, 2021, according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The authors focused on 3 main topics: 1) TXA, 2) liposuction, and 3) complications. We included articles evaluating the potential blood-sparing effects of TXA in liposuction. Studies were excluded if they were systematic review articles or protocol papers, animal studies, conference abstracts, survey studies, or non-English publications.
UNASSIGNED: A total of 711 articles were identified, with 1 retrospective and 4 prospective (3 randomized) studies meeting our inclusion criteria. TXA was used in various forms: administered intravenously either on induction or after the procedure, mixed into the tumescent solution, or infiltrated into the liposuction sites after lipoaspiration. A significantly smaller reduction in hematocrit was noted in the TXA group compared with that in the non-TXA group (p<0.001) despite a significantly greater amount of lipoaspirate removed in the TXA group (p<0.001). Patients in non-TXA cohorts experienced adverse effects (such as seroma and need for transfusion) that were not seen in TXA cohorts.
UNASSIGNED: TXA use in patients undergoing liposuction seems to be associated with a beneficial blood-sparing effect, which may enhance safety in this population. Future studies should aim to determine the optimal route and dosing for TXA in liposuction.
UNASSIGNED: Level IV.
摘要：
■氨甲环酸（TXA）已用于改善许多外科手术中的出血结果。然而,它在吸脂术中的保血效果还没有得到很好的证实。
■使用PubMed进行了系统的文献检索，Embase,护理和相关健康文献累积指数(CINAHL)，CochraneCentral,ClinicalTrials.gov,和WorldWideScience.org数据库从成立到2021年10月8日，根据系统审查和荟萃分析（PRISMA）指南的首选报告项目。作者主要讨论了3个主题：1)TXA，2）吸脂术，3）并发症。我们纳入了评估TXA在吸脂术中潜在的血液保护作用的文章。如果研究是系统综述文章或协议文件，则被排除在外。动物研究,会议摘要，调查研究，或非英文出版物。
■共识别出711篇文章，1项回顾性研究和4项前瞻性(3项随机)研究符合我们的纳入标准.TXA以多种形式使用：诱导时或手术后静脉内给药，混入肿胀溶液中，或在脂肪抽吸后渗入吸脂部位。尽管TXA组去除的脂肪抽吸物的量明显更多(p<0.001),但与非TXA组相比,TXA组的血细胞比容的降低显著更小(p<0.001)。非TXA队列中的患者经历了在TXA队列中未看到的不良反应（例如血清肿和需要输血）。
■在接受吸脂术的患者中使用TXA似乎与有益的血液保护作用有关，这可能会提高这些人群的安全性。未来的研究应旨在确定TXA在吸脂术中的最佳途径和剂量。
■四级。
■使用PubMed进行了系统的文献检索，Embase,护理和相关健康文献累积指数(CINAHL)，CochraneCentral,ClinicalTrials.gov,和WorldWideScience.org数据库从成立到2021年10月8日，根据系统审查和荟萃分析（PRISMA）指南的首选报告项目。作者主要讨论了3个主题：1)TXA，2）吸脂术，3）并发症。我们纳入了评估TXA在吸脂术中潜在的血液保护作用的文章。如果研究是系统综述文章或协议文件，则被排除在外。动物研究,会议摘要，调查研究，或非英文出版物。
■共识别出711篇文章，1项回顾性研究和4项前瞻性(3项随机)研究符合我们的纳入标准.TXA以多种形式使用：诱导时或手术后静脉内给药，混入肿胀溶液中，或在脂肪抽吸后渗入吸脂部位。尽管TXA组去除的脂肪抽吸物的量明显更多(p<0.001),但与非TXA组相比,TXA组的血细胞比容的降低显著更小(p<0.001)。非TXA队列中的患者经历了在TXA队列中未看到的不良反应（例如血清肿和需要输血）。
■在接受吸脂术的患者中使用TXA似乎与有益的血液保护作用有关，这可能会提高这些人群的安全性。未来的研究应旨在确定TXA在吸脂术中的最佳途径和剂量。
■四级。
